Cryptogenic Cirrhosis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CRY036 MIFTS: 36	Cryptogenic Cirrhosis Categories: Liver diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Cryptogenic Cirrhosis

MalaCards integrated aliases for Cryptogenic Cirrhosis:

Name: Cryptogenic Cirrhosis ²⁵

Cirrhosis, Cryptogenic ²⁵ ²⁹ ⁶ ³⁹ ⁷¹

Classifications:

MalaCards categories:
Anatomical: Liver diseases

See all MalaCards categories (disease lists)

External Ids:

UMLS ⁷¹ C0267809

Sources

Summaries for Cryptogenic Cirrhosis

Genetics Home Reference : ²⁵ Cryptogenic cirrhosis is a condition that impairs liver function. People with this condition develop irreversible liver disease caused by scarring of the liver (cirrhosis), typically in mid- to late adulthood. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. Minor damage to the liver can be repaired by the body. However, severe or long-term damage can lead to the replacement of normal liver tissue with scar tissue. In the early stages of cryptogenic cirrhosis, people often have no symptoms because the liver has enough normal tissue to function. Signs and symptoms become apparent as more of the liver is replaced by scar tissue. Affected individuals can experience fatigue, weakness, loss of appetite, weight loss, nausea, swelling (edema), enlarged blood vessels, and yellowing of the skin and whites of the eyes (jaundice). People with cryptogenic cirrhosis may develop high blood pressure in the vein that supplies blood to the liver (portal hypertension). Cryptogenic cirrhosis can lead to type 2 diabetes, although the mechanism is unclear. Some people with cryptogenic cirrhosis develop cancer of the liver (hepatocellular cancer).

MalaCards based summary : Cryptogenic Cirrhosis, also known as cirrhosis, cryptogenic, is related to liver cirrhosis and non-alcoholic fatty liver disease. An important gene associated with Cryptogenic Cirrhosis is KRT18 (Keratin 18), and among its related pathways/superpathways are Folate Metabolism and Formation of Fibrin Clot (Clotting Cascade). The drugs Zinc and Insulin aspart have been mentioned in the context of this disorder. Affiliated tissues include liver, skin and eye, and related phenotypes are growth/size/body region and liver/biliary system

Sources

Related Diseases for Cryptogenic Cirrhosis

Diseases related to Cryptogenic Cirrhosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 197)

#	Related Disease	Score	Top Affiliating Genes
1	liver cirrhosis	32.1	KRT8 KRT18 HFE F2
2	non-alcoholic fatty liver disease	32.1	SERPINE1 KRT18 HFE
3	autoimmune hepatitis	30.7	KRT8 KRT18 F2
4	liver disease	30.2	KRT8 KRT18 HFE F2
5	hepatitis c	30.0	KRT8 KRT18 HFE
6	viral hepatitis	29.7	KRT8 KRT18 HFE F2
7	cholecystitis	29.7	KRT18 F2
8	varicose veins	28.6	MTHFR HFE F5 F2
9	non-alcoholic steatohepatitis	10.6
10	fatty liver disease	10.6
11	neurenteric cyst	10.4	KRT8 KRT18
12	proliferating trichilemmal cyst	10.4	KRT8 KRT18
13	intrahepatic gall duct cancer	10.3	KRT8 KRT18
14	portal hypertension	10.3
15	primary biliary cirrhosis	10.3
16	odontoma	10.3	KRT8 KRT18
17	mucinous tubular and spindle renal cell carcinoma	10.3	KRT8 KRT18
18	cutaneous adenocystic carcinoma	10.3	KRT8 KRT18
19	lymphoepithelioma-like thymic carcinoma	10.3	KRT8 KRT18
20	lymphoepithelioma-like carcinoma	10.3	KRT8 KRT18
21	cholangitis	10.3
22	pleomorphic carcinoma	10.2	KRT8 KRT18
23	hemochromatosis, type 1	10.2
24	hepatitis c virus	10.2
25	cholangitis, primary sclerosing	10.2
26	sclerosing cholangitis	10.2
27	mammary paget's disease	10.2	KRT8 KRT18
28	hepatocellular carcinoma	10.2
29	hypertriglyceridemia, familial	10.2
30	paracetamol poisoning	10.1	F5 F2
31	fatty liver disease, nonalcoholic 1	10.1
32	alpha-1-antitrypsin deficiency	10.1
33	hepatitis b	10.1
34	hepatopulmonary syndrome	10.1
35	dic in newborn	10.1	SERPINE1 F2
36	prothrombin deficiency, congenital	10.1	F5 F2
37	sagittal sinus thrombosis	10.1	F5 F2
38	spindle cell carcinoma	10.1	KRT8 KRT18
39	hemoglobin e disease	10.1	F5 F2
40	mediastinitis	10.1	F5 F2
41	sticky platelet syndrome	10.1	SERPINE1 F5
42	sneddon syndrome	10.0	F5 F2
43	factor x deficiency	10.0	F5 F2
44	peripheral vertigo	10.0	F5 F2
45	factor v deficiency	10.0	F5 F2
46	hepatitis	10.0	KRT8 KRT18 F2
47	hypercholesterolemia, familial, 1	10.0
48	celiac disease 1	10.0
49	body mass index quantitative trait locus 11	10.0
50	body mass index quantitative trait locus 9	10.0

Graphical network of the top 20 diseases related to Cryptogenic Cirrhosis:

Sources

Symptoms & Phenotypes for Cryptogenic Cirrhosis

MGI Mouse Phenotypes related to Cryptogenic Cirrhosis:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	growth/size/body region	MP:0005378	9.76	F2 F5 HFE KRT18 KRT8 LIPA
2	liver/biliary system	MP:0005370	9.5	F5 HFE KRT18 KRT8 LIPA MTHFR
3	mortality/aging	MP:0010768	9.23	F2 F5 HFE KRT18 KRT8 LIPA

Sources

Drugs & Therapeutics for Cryptogenic Cirrhosis

Drugs for Cryptogenic Cirrhosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Zinc

Approved, Investigational

Phase 4

7440-66-6

32051

Synonyms:

alpha D Mannosidase

alpha D Mannoside mannohydrolase

alpha Mannosidase

alpha Mannosidase b

alpha-D-Mannosidase

alpha-D-Mannoside mannohydrolase

alpha-Mannosidase

alpha-Mannosidase, lysosomal

alpha-Mannosidase, neutral

Dietary zinc

LAMAN

Lysosomal alpha mannosidase

Lysosomal alpha-mannosidase

Mannohydrolase, alpha-D-mannoside

Mannosidase b, alpha

Neutral alpha mannosidase

Neutral alpha-mannosidase

Topostin b

Zinc cation

ZINC ion

Zinc, chelated

Zinc, elemental

Zinc, ion (ZN2+)

Zincum metallicum

ZN(2+)

ZN(II)

ZN2+

Insulin aspart

Approved

Phase 4

116094-23-6

16132418

Synonyms:

(AspB28)-human insulin

1024611-56-0

116094-23-6

139532-40-4

28(sup B)-L-Aspartic acid-insulin (human)

877034-90-7

Aspart

Aspart insulin

Aspart Insulin

AspB28-insulin (human)

B28-Aspart-Insulin

B28-Asp-insulin

INA-X 14

Insulin aspart

Insulin aspart [USAN]

Insulin aspart protamine

Insulin aspart protamine recombinant

Insulin aspart recombinant

Insulin X14

Insulin, aspart protamine, human

Insulin, aspart, human

Insulin,aspart protamine

Insulina asparta

LS-185932

NovoLog

Novolog mix 70/30

NovoMix 30

NovoRapid

NovoRapid 30 Mix

UNII-D933668QVX

Exenatide

Approved, Investigational

Phase 4

141758-74-9

15991534

Synonyms:

141732-76-5

141758-74-9

286014-72-0

335149-21-8

AC 2993

AC 2993 LAR

AC 2993A

Byetta

C074031

CHEBI:490990

CHEMBL414357

Ex4 peptide

Exenatida

Exenatide

Exenatide synthetic

Exenatide Synthetic

Exendin 4

Exendin 4 (Heloderma suspectum)

Exendin-4

Extendin-4

LY2148568

Synthetic exendin-4

UNII-9P1872D4OL

Insulin detemir

Approved

Phase 4

169148-63-4

5311023

insulin

Phase 4

Hypoglycemic Agents

Phase 4

Insulin, Globin Zinc

Phase 4

Liver Extracts

Phase 4

Anti-Obesity Agents

Phase 4

Incretins

Phase 4

Hormone Antagonists

Phase 4

Hormones

Phase 4

Metformin

Approved

657-24-9

14219 4091

Synonyms:

1,1-Dimethyl biguanide

1,1-Dimethylbiguanide

3-(diaminomethylidene)-1,1-dimethylguanidine

657-24-9

AC1L1HE4

AKOS000121065

Apo-Metformin

BIDD:GT0697

BPBio1_000009

BRD-K79602928-003-04-1

BSPBio_000007

BSPBio_002314

C07151

C4H11N5

CAS-1115-70-4

CCRIS 9321

CHEBI:6801

CHEMBL1431

CID4091

cMAP_000016

D04966

DB00331

Diabetosan

Diabex

Dimethylbiguanid

Dimethylbiguanide

Dimethylbiguanidine

Dimethyldiguanide

Dimethylguanylguanidine

DMGG

EINECS 211-517-8

Fluamine

Flumamine

Fortamet

Gen-Metformin

Glifage

Gliguanid

Glucophage

Glucophage XR

Glumetza

Glycon

Haurymelin

HMS2089D19

HSCI1_000295

Islotin

KBio2_002310

KBio2_004878

KBio2_007446

KBio3_002790

KBioGR_002310

KBioSS_002312

LA-6023

LS-43899

Melbin

metformin

Metformin

Metformin (USAN/INN)

Metformin [USAN:INN:BAN]

Metformin HCL

metformin hydrochloride

Metformina

Metformina [DCIT]

Metformina [Spanish]

Metformine

Metformine [INN-French]

Metforminum

Metforminum [INN-Latin]

Metiguanide

MolPort-002-929-560

MolPort-004-288-389

MolPort-005-767-418

Mylan-Metformin

N,N-Dimethylbiguanide

N,N-Dimethyldiguanide

N,N-dimethylimidodicarbonimidic diamide

N1,N1-Dimethylbiguanide

NCGC00016564-01

NCGC00016564-02

NCGC00016564-03

NNDG

Novo-Metformin

Nu-Metformin

PMS-Metformin

Prestwick0_000004

Prestwick1_000004

Prestwick2_000004

Prestwick3_000004

Ran-Metformin

Ratio-Metformin

Riomet

S2483_Selleck

Sandoz Metformin

Siofor

SPBio_001928

STK011633

T5895664

Teva-Metformin

UNII-9100L32L2N

ZINC12859773

Pentoxifylline

Approved, Investigational

6493-05-6

4740

Synonyms:

1-(5-Oxohexyl)-3,7-dimethylxanthine

1-(5-Oxohexyl)theobromine

1,2,3,6-Tetrahydro-3,7-dimethyl-1-(5-oxohexyl)-2,6-purindion

2a3c

3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione

3,7-Dimethyl-1-(5-oxohexyl) xantine

3,7-Dimethyl-1-(5-oxohexyl)-1H,3H-purin-2,6-dione

3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione

3,7-Dimethyl-1-(5-oxo-hexyl)-3,7-dihydro-purine-2,6-dione

3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione

3,7-Dimethyl-1-(5-oxohexyl)xanthine

3,7-Dimethyl-1-(5-oxohexyl)xantine

5-26-14-00081 (Beilstein Handbook Reference)

6493-05-6

AB00052363

AC1L1IUN

Agapurin

Agapurin Retard

AKOS000541484

Azupentat

BAS 00897429

BB_SC-2111

BIDD:GT0174

BL 191

BL191

BL-191

BPBio1_000167

BRD-K57569181-001-05-1

BRN 0558929

BSPBio_000151

BSPBio_003439

C07424

C13H18N4O3

CAS-1677687

CCRIS 6832

CHEMBL628

CID4740

cis-9-Octadecenoyl coenzyme A

CPD000035998

D00501

D010431

DB00806

Dimethyloxohexylxanthine

DivK1c_000729

Durapental

EHT 0201

EHT0201

EHT-0201

EHT-201

EINECS 229-374-5

EU-0100936

Hemovas

HMS1568H13

HMS1922E16

HMS2051N06

HMS2090H13

HMS2093G21

HMS502E11

I06-1592

IDI1_000729

Ikomio

IN1161

KBio1_000729

KBio2_001924

KBio2_004492

KBio2_007060

KBio3_002942

KBioGR_000893

KBioSS_001924

Lopac0_000936

Lopac-P-1784

LS-149385

MLS000079026

MLS000758298

MLS001201764

MolPort-001-823-263

NCGC00015801-01

NCGC00015801-02

NCGC00015801-04

NCGC00015801-10

NCGC00067069-02

NCGC00067069-03

NCGC00067069-04

NCGC00067069-05

NCGC00178062-01

NCGC00178062-02

NINDS_000729

NSC 637086

NSC637086

Oxpentifylline

P 1784

PDSP1_001015

PDSP2_000999

Pentoxifilina

Pentoxifilina [INN-Spanish]

Pentoxifyllin

pentoxifylline

Pentoxifylline

Pentoxifylline (JAN/USP/INN)

Pentoxifylline [USAN:INN:JAN]

Pentoxifyllinum

Pentoxifyllinum [INN-Latin]

Pentoxil

Pentoxil (TN)

Pentoxiphyllin

Pentoxiphylline

Pentoxiphyllium

Pentoxyfylline

PENTOXYPHYLINE

Pentoxyphyllin

Pentoxyphylline

PNX

Prestwick_608

Prestwick0_000196

Prestwick1_000196

Prestwick2_000196

Prestwick3_000196

Ralofect

Rentylin

SAM001247011

SMR000035998

SPBio_001221

SPBio_002072

Spectrum_001444

SPECTRUM1503611

Spectrum2_001181

Spectrum3_001820

Spectrum4_000227

Spectrum5_001161

SR-01000075641-4

STK177321

Torental

Trental

Trental (TN)

UNII-SD6QCT3TSU

Vasofirin

Vazofirin

ZINC01530776

Methionine

Approved, Nutraceutical

63-68-3

6137

Synonyms:

(2S)-2-amino-4-(Methylsulfanyl)butanoate

(2S)-2-amino-4-(methylsulfanyl)butanoic acid

(2S)-2-amino-4-(Methylsulfanyl)butanoic acid

(2S)-2-amino-4-(Methylsulphanyl)butanoate

(2S)-2-amino-4-(Methylsulphanyl)butanoic acid

(L)-Methionine

(S)-(+)-Methionine

(S)-2-amino-4-(methylthio)Butanoate

(S)-2-amino-4-(methylthio)-Butanoate

(S)-2-amino-4-(methylthio)butanoic acid

(S)-2-amino-4-(methylthio)Butanoic acid

(S)-2-amino-4-(methylthio)-Butanoic acid

(S)-2-amino-4-(methylthio)Butyrate

(S)-2-amino-4-(methylthio)butyric acid

(S)-2-amino-4-(methylthio)Butyric acid

(S)-methionine

(S)-Methionine

2-amino-4-(methylthio)Butyrate

2-amino-4-(methylthio)Butyric acid

2-amino-4-Methylthiobutanoate

2-amino-4-Methylthiobutanoic acid

a-amino-g-Methylmercaptobutyrate

a-amino-g-Methylmercaptobutyric acid

Acimethin

alpha-amino-alpha-Aminobutyric acid

alpha-amino-gamma-Methylmercaptobutyrate

alpha-amino-gamma-Methylmercaptobutyric acid

Cymethion

gamma-methylthio-alpha-Aminobutyrate

gamma-methylthio-alpha-Aminobutyric acid

g-methylthio-a-Aminobutyrate

g-methylthio-a-Aminobutyric acid

H-Met-H

H-Met-OH

L(-)-amino-alpha-amino-alpha-Aminobutyric acid

L(-)-amino-gamma-Methylthiobutyric acid

L-(−)-methionine

L-(-)-Methionine

L-2-amino-4-(methylthio)Butyric acid

L-2-amino-4-Methylthiobutyric acid

L-a-amino-g-Methylmercaptobutyrate

L-a-amino-g-Methylmercaptobutyric acid

L-a-amino-g-Methylthiobutyrate

L-a-amino-g-Methylthiobutyric acid

L-a-Amino-g-methylthiobutyric acid

L-alpha-amino-gamma-Methylmercaptobutyrate

L-alpha-amino-gamma-Methylmercaptobutyric acid

L-alpha-amino-gamma-Methylthiobutyrate

L-alpha-amino-gamma-Methylthiobutyric acid

L-gamma-methylthio-alpha-Aminobutyric acid

Liquimeth

L-Isomer methionine

L-Methionin

L-Methionine

L-Methioninum

L-α-amino-γ-methylmercaptobutyrate

L-α-amino-γ-methylmercaptobutyric acid

Mepron

Met

Methilanin

Methionine

METHIONINE

Methionine, L isomer

Methionine, L-isomer

Methioninum

Metionina

neo-Methidin

Pedameth

Poly-L-methionine

Polymethionine

S-Methionine

S-Methyl-L-homocysteine

Toxin war

Hematinics

Platelet Aggregation Inhibitors

Free Radical Scavengers

Antioxidants

Vasodilator Agents

Protective Agents

Phosphodiesterase Inhibitors

Radiation-Protective Agents

Antibodies

Immunoglobulins

Interventional clinical trials:

(show all 13)

#	Name	Status	NCT ID	Phase	Drugs
1	A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)	Completed	NCT01006889	Phase 4	Exenatide
2	An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency	Completed	NCT01371825	Phase 2, Phase 3	Sebelipase alfa (SBC-102)
3	An Open Label Multicenter Extension Study to Evaluate the Long-term Efficacy and Safety of SBC-102 in Children With Lysosomal Acid Lipase Deficiency Who Previously Received Treatment With SBC-102	Terminated	NCT01473875	Phase 2, Phase 3	SBC-102
4	A Phase 2, Open Label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Sebelipase Alfa in Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency	Terminated	NCT02193867	Phase 2	Sebelipase Alfa
5	Measurement of Fibrinogen in Patients With Systemic Inflammatory Response Syndrome, Sepsis, Chronicle Liver Disease or After Lysis on Intensive Care Units	Unknown status	NCT01169168
6	Assessment of the Prevalence of Lysosomal Acid Lipase Deficiency in Patients Waiting for a Liver Transplant.	Unknown status	NCT02852304
7	Assessement of the Prevalence of Lysosomal Acid Lipase Deficiency in Liver Post-transplant Patients	Unknown status	NCT02851550
8	Non Alcoholic Fatty Liver Disease (NAFLD) in Hong Kong: Natural History and Development of Liver Complications	Unknown status	NCT00577044
9	Prevalence and Clinical Characteristics of the Patients With Liver Cirrhosis and Different Glucose Metabolism Disorders - A Prospective Study.	Unknown status	NCT01396954
10	Effect of Metformin on Disease Progression in Patients With Cryptogenic Cirrhosis (NASH-related Cirrhosis) With Diabetes or Impaired Glucose Tolerance or Insulin Resistance: a Prospective Randomized, Open Labeled, Clinical Trial"	Completed	NCT02234440		Metformin;Insulin
11	A Randomized Controlled Trial to Study the Efficacy of S-adenosyl Methionine (SAMe) Versus Pentoxiphylline in Patients With Non-alcoholic Steatohepatitis With Fibrosis.	Completed	NCT02231333		S-adenosylmethionine (SAMe);pentoxiphylline (PTX)
12	The Frequency of Cholesteryl Ester Storage Disease in Children With Unexplained Transaminase Elevation and Chronic Liver Disease	Completed	NCT02372513
13	Undetected Bartonella Spp. Infection Puts Liver Transplant Patients at Great Risk	Recruiting	NCT02595710

Search NIH Clinical Center for Cryptogenic Cirrhosis

Sources

Genetic Tests for Cryptogenic Cirrhosis

Genetic tests related to Cryptogenic Cirrhosis:

#	Genetic test	Affiliating Genes
1	Cirrhosis, Cryptogenic ²⁹

Sources

Anatomical Context for Cryptogenic Cirrhosis

MalaCards organs/tissues related to Cryptogenic Cirrhosis:

⁴⁰

Liver, Skin, Eye, Kidney, Testes, Neutrophil, Bone

Sources

Publications for Cryptogenic Cirrhosis

Articles related to Cryptogenic Cirrhosis:

(show top 50) (show all 737)

#	Title	Authors	PMID	Year
1	Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients. ⁶¹	Enooku K...Koike K	31602526	2020
2	Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of non-alcoholic fatty liver disease. ⁶¹	Baratta F...Del Ben M	31392821	2019
3	Metastatic cholangiocarcinoma in a patient with undiagnosed Wilson disease. ⁶¹	Mavilia MG...Forouhar F	31167735	2019
4	Acute-on-Chronic Liver Failure: Etiology of Chronic and Acute Precipitating Factors and Their Effect on Mortality. ⁶¹	Gawande A...Nijhawan S	31889750	2019
5	Cryptogenic cirrhosis: Old and new perspectives in the era of molecular and genomic medicine. ⁶¹	Nalbantoglu I...Jain D	31395291	2019
6	Etiology of cirrhosis in the young. ⁶¹	Olave MC...Jain D	31698008	2019
7	Effects of Share 35 Policy on Liver Transplantation Outcomes for Patients With Nonalcoholic Steatohepatitis. ⁶¹	Zhang Y...Boktour MR	31146627	2019
8	Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease? ⁶¹	Baratta F...Del Ben M	31435171	2019
9	Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis. ⁶¹	Eshraghian A...Malek-Hosseini SA	31431413	2019
10	Cryptogenic liver cirrhosis and hepatitis E virus (HEV): Are they related? ⁶¹	Akyuz F...Kaymakoglu S	31130469	2019
11	Clinical course and mortality by etiology of liver cirrhosis in Sweden: a population based, long-term follow-up study of 1317 patients. ⁶¹	Nilsson E...Prytz H	30957910	2019
12	Position statement on the diagnosis and management of non-alcoholic fatty liver disease. ⁶¹	Alswat KA...Al-Osaimi A	31219486	2019
13	NASH Is the Most Rapidly Growing Etiology for Acute-on-Chronic Liver Failure-Related Hospitalization and Disease Burden in the United States: A Population-Based Study. ⁶¹	Axley P...Singal AK	30861321	2019
14	Predisposing Conditions to Pediatric Hepatocellular Carcinoma and Association With Outcomes: Single-center Experience. ⁶¹	Cowell E...Miloh T	30676520	2019
15	Outcome of Liver Transplant Patients With Intraoperative-Detected Portal Vein Thrombosis: A Retrospective Cohort Study in Shiraz, Iran. ⁶¹	Bagheri Lankarani K...Malekhosseini SA	30995894	2019
16	The Frequency of Lysosomal Acid Lipase Deficiency in Children With Unexplained Liver Disease. ⁶¹	Kuloglu Z...National LAL-D Study Group	30540705	2019
17	Evaluation of Underlying Liver Disease and Its Severity in Children Referred for Liver Transplant: a Single-Center Report From Nemazee Hospital of Shiraz. ⁶¹	Dehghani SM...Mardani S	30836904	2019
18	Fibrinolysis Shutdown Is Associated With Thrombotic and Hemorrhagic Complications and Poorer Outcomes After Liver Transplantation. ⁶¹	Nicolau-Raducu R...Raveh Y	30548128	2019
19	Complete Heart Block due to Octreotide Infusion in Patient with Cryptogenic Cirrhosis. ⁶¹	Icen YK...Koc M	30911266	2019
20	Senescent Hepatocytes in Decompensated Liver Show Reduced UPRMT and Its Key Player, CLPP, Attenuates Senescence In Vitro. ⁶¹	Sen B...Ramakrishna G	30878663	2019
21	Technical success and outcomes in pediatric patients undergoing transjugular intrahepatic portosystemic shunt placement: a 20-year experience. ⁶¹	Ghannam JS...Gemmete JJ	30291382	2019
22	Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand. ⁶¹	Calzadilla-Bertot L...Adams LA	30609187	2019
23	Waiting List Mortality and Transplant Rates for NASH Cirrhosis When Compared With Cryptogenic, Alcoholic, or AIH Cirrhosis. ⁶¹	Thuluvath PJ...Savva Y	29985186	2019
24	Lysosomal Acid Lipase: Can it be a New Non-Invasive Serum Biomarker of Cryptogenic Liver Fibrosis and Cirrhosis? ⁶¹	Gravito-Soares M...Tome L	31113613	2019
25	Poor Survival After Retransplantation in NASH Cirrhosis. ⁶¹	Thuluvath AJ...Savva Y	29470354	2019
26	A decompensated cryptogenic cirrhosis? No, a late liver histiocytosis! ⁶¹	Ouizeman DJ...Anty R	30077466	2018
27	The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. ⁶¹	Younossi Z...Goodman Z	30144554	2018
28	Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries. ⁶¹	Holmer M...Hagstrom H	29630771	2018
29	Significance of Occult Hepatitis C Virus Infection in Liver Transplant Patients With Cryptogenic Cirrhosis. ⁶¹	Yaghobi R...Moayedi J	30346262	2018
30	NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis. ⁶¹	Giannini EG...Marabotto E	30227919	2018
31	Reply to: "NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis": Cryptogenic cirrhosis should not be equated with NASH cirrhosis based on UNOS data mining and Bayesian 'doctrine of chances'. ⁶¹	Thuluvath PJ...Savva Y	29983203	2018
32	A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America. ⁶¹	Pinero F...Latin American Liver Research, Education, Awareness Network (LALREAN)	29773419	2018
33	Clinical characteristics and outcomes of hepatocellular carcinoma: results from prospective study, from a tertiary referral center in  Sri Lanka ⁶¹	Bulathsinhala BKS...Dassanayake A	30415518	2018
34	Pernicious anemia associated with cryptogenic cirrhosis: Two case reports and a literature review. ⁶¹	Yan X...Jin J	30278550	2018
35	Non-cirrhotic portal hypertension: an imaging review. ⁶¹	Rajesh S...Arora A	29564495	2018
36	Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016. ⁶¹	Golabi P...Younossi ZM	30075518	2018
37	Identification of rare diseases by screening a population selected on the basis of routine pathology results-the PATHFINDER project: lysosomal acid lipase/cholesteryl ester storage disease substudy. ⁶¹	Reynolds TM...PATHFINDER Project Collaboration group	29358478	2018
38	Case report of high-dose hydroxocobalamin in the treatment of vasoplegic syndrome during liver transplantation. ⁶¹	An SS...McEvoy MD	29573551	2018
39	Role of Glutathione S Transferase M1 and T1 Gene Polymorphism in Hepatitis B Related Liver Diseases and Cryptogenic Cirrhosis. ⁶¹	Kapahtia S...Kar P	29892180	2018
40	A growing hepatic mass in a cryptogenic cirrhosis patient. ⁶¹	Song JS...Moon WS	29050462	2018
41	Raised plasma levels of H2S and nitrate predict intrapulmonary vascular dilations: A preliminary report in patients with cryptogenic cirrhosis. ⁶¹	Bera C...Eapen CE	29984390	2018
42	Prevalence of celiac disease among pediatric patients with cryptogenic cirrhosis and effect of gluten-free-diet. ⁶¹	Joshi A...Khatri PC	29948993	2018
43	Telomere Length, Aggregates, and Capture in Cirrhosis. ⁶¹	Laish I...Kitay-Cohen Y	29761675	2018
44	Stratifying Mortality in a Model for End-Stage Liver Disease Waiting List: A Brazilian Single-Center Study. ⁶¹	Martino RB...D'Albuquerque LAC	29661431	2018
45	Liver Transplantation in Cryptogenic Cirrhosis: Outcome Comparisons Between NASH, Alcoholic, and AIH Cirrhosis. ⁶¹	Thuluvath PJ...Savva Y	29215462	2018
46	Well Preserved Renal Function in Children With Untreated Chronic Liver Disease. ⁶¹	Berg UB...Nemeth A	29240010	2018
47	Complete splenic embolization for the treatment of refractory ascites after liver transplantation. ⁶¹	Nutu OA...Jimenez Romero LC	29411988	2018
48	Liver Transplantation in Patients With Hepatocellular Carcinoma Outside the Milan Criteria After Downstaging: Is It Worth It? ⁶¹	Cascales-Campos P...Parrilla P	29579861	2018
49	Follow-up Creatinine Level Is an Important Predictive Factor of In-hospital Mortality in Cirrhotic Patients with Spontaneous Bacterial Peritonitis. ⁶¹	Jun BG...Kim HS	29542304	2018
50	Systematic review with meta-analysis: de novo non-alcoholic fatty liver disease in liver-transplanted patients. ⁶¹	Losurdo G...Di Leo A	29359341	2018

Sources

Genes for Cryptogenic Cirrhosis

Genes related to Cryptogenic Cirrhosis (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	KRT18	Keratin 18	Protein Coding	26.05	GeneCards inferred via : Publications Summaries Variants (show sections)
2	KRT8	Keratin 8	Protein Coding	17.31	GeneCards inferred via : Summaries Variants (show sections)
3	LOC106096416	KRT18 Locus Control Region	Biological Region	7.45	GeneCards inferred via : Variants (show sections)
4	LIPA	Lipase A, Lysosomal Acid Type	Protein Coding	7.14	GeneCards inferred via : Publications (show sections)
5	F2	Coagulation Factor II, Thrombin	Protein Coding	6.79	GeneCards inferred via : Publications (show sections)
6	F5	Coagulation Factor V	Protein Coding	6.79	GeneCards inferred via : Publications (show sections)
7	HFE	Homeostatic Iron Regulator	Protein Coding	6.79	GeneCards inferred via : Publications (show sections)
8	MTHFR	Methylenetetrahydrofolate Reductase	Protein Coding	6.79	GeneCards inferred via : Publications (show sections)
9	SERPINE1	Serpin Family E Member 1	Protein Coding	6.79	GeneCards inferred via : Publications (show sections)

Sources

Variations for Cryptogenic Cirrhosis

Sources

Expression for Cryptogenic Cirrhosis

Search GEO for disease gene expression data for Cryptogenic Cirrhosis.

Sources

Pathways for Cryptogenic Cirrhosis

Pathways related to Cryptogenic Cirrhosis according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Folate Metabolism ¹ Show member pathways Selenium Micronutrient Network ¹ thioredoxin pathway ¹ Vitamin B12 Metabolism ¹	11.66	SERPINE1 MTHFR F2
2	Formation of Fibrin Clot (Clotting Cascade) ⁶⁵ Show member pathways Blood Clotting Cascade ¹ Blood Coagulation Signaling Pathways ⁶⁴ Common Pathway of Fibrin Clot Formation ⁶⁵ Extrinsic Pathway of Fibrin Clot Formation ⁶⁵ Extrinsic Prothrombin Activation Pathway ⁶³ Intrinsic Pathway of Fibrin Clot Formation ⁶⁵	11.33	SERPINE1 F5 F2
3	Complement and coagulation cascades ¹ ³⁶	10.96	SERPINE1 F5 F2

Sources

GO Terms for Cryptogenic Cirrhosis

Biological processes related to Cryptogenic Cirrhosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	hemostasis	GO:0007599	9.43	F5 F2
2	extrinsic apoptotic signaling pathway	GO:0097191	9.4	KRT8 KRT18
3	acute-phase response	GO:0006953	9.37	HFE F2
4	positive regulation of receptor-mediated endocytosis	GO:0048260	9.32	SERPINE1 HFE
5	fibrinolysis	GO:0042730	9.26	SERPINE1 F2
6	positive regulation of blood coagulation	GO:0030194	9.16	SERPINE1 F2
7	hepatocyte apoptotic process	GO:0097284	8.96	KRT8 KRT18
8	negative regulation of fibrinolysis	GO:0051918	8.62	SERPINE1 F2

Molecular functions related to Cryptogenic Cirrhosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	scaffold protein binding	GO:0097110	8.62	KRT8 KRT18

Sources

Sources for Cryptogenic Cirrhosis

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia